Tm Bioscience Launches P450-2D6 Kit, Firms Finances, Prepares for Cystic Fibrosis Rollout | GenomeWeb

Toronto-based Tm Bioscience last week launched its Tag-It CYP450-2D6 mutation detection kit — within days after Roche officially introduced its Affymetrix-platform diagnostic CYP450 GeneChip tests to great fanfare in the mainstream media.

“This [P450-2D6] is a rapidly growing test market for the pharmaceutical and the clinical sectors,” said Jeremy Bridge-Cook, Tm Bioscience vice president for business development. He told BioArray News that Tm is looking to compete with Roche and other test-makers on the basis of cost and efficiency.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.